These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
133 related articles for article (PubMed ID: 8104720)
61. C-erbB-3 in human breast carcinoma: expression and relation to prognosis and established prognostic indicators. Travis A; Pinder SE; Robertson JF; Bell JA; Wencyk P; Gullick WJ; Nicholson RI; Poller DN; Blamey RW; Elston CW; Ellis IO Br J Cancer; 1996 Jul; 74(2):229-33. PubMed ID: 8688326 [TBL] [Abstract][Full Text] [Related]
62. Cysteine proteinase inhibitor cystatin A in breast cancer. Kuopio T; Kankaanranta A; Jalava P; Kronqvist P; Kotkansalo T; Weber E; Collan Y Cancer Res; 1998 Feb; 58(3):432-6. PubMed ID: 9458085 [TBL] [Abstract][Full Text] [Related]
63. Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers. Sjögren S; Inganäs M; Lindgren A; Holmberg L; Bergh J J Clin Oncol; 1998 Feb; 16(2):462-9. PubMed ID: 9469329 [TBL] [Abstract][Full Text] [Related]
64. [Comparative immunohistochemical study of invasive duct carcinoma and Paget's disease of the breast with c-erbB-2 overexpression]. Petrov SV; Raskin GA; Khasanov RSh; Tsyplakov DE Arkh Patol; 2006; 68(5):10-4. PubMed ID: 17144522 [TBL] [Abstract][Full Text] [Related]
66. Tumor microvessel density, p53 expression, tumor size, and peritumoral lymphatic vessel invasion are relevant prognostic markers in node-negative breast carcinoma. Gasparini G; Weidner N; Bevilacqua P; Maluta S; Dalla Palma P; Caffo O; Barbareschi M; Boracchi P; Marubini E; Pozza F J Clin Oncol; 1994 Mar; 12(3):454-66. PubMed ID: 7509851 [TBL] [Abstract][Full Text] [Related]
67. The effect of Paget disease on axillary lymph node metastases and survival in invasive ductal carcinoma. Wong SM; Freedman RA; Sagara Y; Stamell EF; Desantis SD; Barry WT; Golshan M Cancer; 2015 Dec; 121(24):4333-40. PubMed ID: 26376021 [TBL] [Abstract][Full Text] [Related]
68. Genetic alterations in c-erbB-2 protooncogene as prognostic markers in human primary breast tumors. Nagai MA; Marques LA; Torloni H; Brentani MM Oncology; 1993; 50(6):412-7. PubMed ID: 7901824 [TBL] [Abstract][Full Text] [Related]
69. Immunohistochemical localization of metallothionein in human breast cancer in comparison with cathepsin D, stromelysin-1, CD44, extracellular matrix components, P53, Rb, C-erbB-2, EGFR, steroid receptor content and proliferation. Ioachim E; Kamina S; Demou A; Kontostolis M; Lolis D; Agnantis NJ Anticancer Res; 1999; 19(3A):2133-9. PubMed ID: 10470161 [TBL] [Abstract][Full Text] [Related]
70. The neu-protein and breast cancer. De Potter CR; Schelfhout AM Virchows Arch; 1995; 426(2):107-15. PubMed ID: 7757280 [TBL] [Abstract][Full Text] [Related]
71. Keratinocyte induced chemotaxis in the pathogenesis of Paget's disease of the breast. de Potter CR; Eeckhout I; Schelfhout AM; Geerts ML; Roels HJ Histopathology; 1994 Apr; 24(4):349-56. PubMed ID: 7519165 [TBL] [Abstract][Full Text] [Related]
72. Nuclear and flow cytometric characteristics associated with overexpression of the c-erbB-2 oncoprotein in breast carcinoma. Poller DN; Galea M; Pearson D; Bell J; Gullick WJ; Elston CW; Blamey RW; Ellis IO Breast Cancer Res Treat; 1991 Dec; 20(1):3-10. PubMed ID: 1687505 [TBL] [Abstract][Full Text] [Related]
74. Expression of the c-erbB-2 proto-oncogene product and nuclear DNA content in benign and malignant human breast parenchyma. Schimmelpenning H; Eriksson ET; Falkmer UG; Azavedo E; Svane G; Auer GU Virchows Arch A Pathol Anat Histopathol; 1992; 420(5):433-40. PubMed ID: 1350695 [TBL] [Abstract][Full Text] [Related]
75. [Clinical evaluation of ErbB-2 protein in tissue extract using an enzyme immuno assay (ErbB-2 EIA "Nichirei")]. Sugano K; Kitajima M; Ishii M; Koyama H; Kasumi F; Demura R; Mori S; Ohkura H Gan To Kagaku Ryoho; 1994 Sep; 21(12):1957-66. PubMed ID: 7916182 [TBL] [Abstract][Full Text] [Related]
76. Prognostic significance of the overexpression of c-erbB-2 protein in adenocarcinoma of the uterine cervix. Kihana T; Tsuda H; Teshima S; Nomoto K; Tsugane S; Sonoda T; Matsuura S; Hirohashi S Cancer; 1994 Jan; 73(1):148-53. PubMed ID: 7506116 [TBL] [Abstract][Full Text] [Related]
77. Immunohistochemical study on overexpression of c-erbB-2 protein in human breast cancer: its correlation with gene amplification and long-term survival of patients. Tsuda H; Hirohashi S; Shimosato Y; Tanaka Y; Hirota T; Tsugane S; Shiraishi M; Toyoshima K; Yamamoto T; Terada M Jpn J Cancer Res; 1990 Apr; 81(4):327-32. PubMed ID: 1973161 [TBL] [Abstract][Full Text] [Related]
78. Is c-erb B-2 a predictor for recurrent disease in early stage breast cancer? Pierce LJ; Merino MJ; D'Angelo T; Barker EA; Gilbert L; Cowan KH; Steinberg SM; Glatstein E Int J Radiat Oncol Biol Phys; 1994 Jan; 28(2):395-403. PubMed ID: 7903962 [TBL] [Abstract][Full Text] [Related]
79. An evaluation of immunoreactivity for c-erbB-2 protein as a marker of poor short-term prognosis in breast cancer. Walker RA; Gullick WJ; Varley JM Br J Cancer; 1989 Sep; 60(3):426-9. PubMed ID: 2571356 [TBL] [Abstract][Full Text] [Related]
80. Immunohistochemical demonstration of c-erbB-2 protein in mammary ductal carcinoma in situ. Bartkova J; Barnes DM; Millis RR; Gullick WJ Hum Pathol; 1990 Nov; 21(11):1164-7. PubMed ID: 1977679 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]